Skip to main content
XENE
NASDAQ Life Sciences

Xenon Pharmaceuticals 完成超额发行，净筹资 7.077 亿美元

feedReported by Wiseek News
Sentiment info
Neutral
Importance info
8
Price
$57.9
Mkt Cap
$4.817B
52W Low
$26.74
52W High
$63.95
Market data snapshot near publication time

summarizeSummary

Xenon Pharmaceuticals 已成功完成其承销的公开发行，获得约 7.077 亿美元的净收益。这一最终金额明显高于此前宣布的 6.5 亿美元，反映了承销商对额外股份的全部行权。这次资本筹集是在 3 月 9 日宣布其 X-TOLE2 3 期研究 azetukalner 顶线结果极为积极之后进行的。以每股 57.00 美元的价格定价的本次发行，显著提高了公司的流动性，为一般公司目的（包括推进其临床管线）提供了大量资金。本次超额融资活动的成功完成加强了 Xenon 在推进其主要药物候选物时的财务状况。

在该公告发布时，XENE的交易价格为$57.90，交易所为NASDAQ，所属行业为Life Sciences，市值约为$48.2亿。 52周交易区间为$26.74至$63.95。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed XENE - Latest Insights

XENE
Apr 22, 2026, 4:02 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Shareholders to Vote on New 2026 Equity Incentive Plan Authorizing up to 7.5M Shares
Sentiment: Neutral
View Wiseek Article
XENE
Mar 12, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Xenon Pharmaceuticals Closes Upsized Offering, Nets $707.7M
Sentiment: Neutral
View Wiseek Article
XENE
Mar 12, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
9
Xenon Pharmaceuticals Closes Upsized $707.7M Public Offering Following Positive Phase 3 Results
Sentiment: Positive
View Wiseek Article
XENE
Mar 11, 2026, 5:47 PM EDT
Filing Type: 424B5
Importance Score:
9
Xenon Pharmaceuticals Finalizes Upsized $650M Public Offering at Premium Price Following Positive Phase 3 Data
Sentiment: Positive
View Wiseek Article
XENE
Mar 10, 2026, 10:41 PM EDT
Source: Reuters
Importance Score:
8
Xenon Pharma Prices Upsized $650M Offering at $57.00 Per Share
Sentiment: Negative
View Wiseek Article
XENE
Mar 10, 2026, 9:23 PM EDT
Filing Type: FWP
Importance Score:
7
Xenon Pharmaceuticals Adds Pre-Funded Warrants to $500M Public Offering
Sentiment: Neutral
View Wiseek Article
XENE
Mar 09, 2026, 4:54 PM EDT
Filing Type: 424B5
Importance Score:
9
Xenon Pharmaceuticals Launches $500M Underwritten Offering at Pre-News Price Following Positive Phase 3 Data
Sentiment: Neutral
View Wiseek Article
XENE
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
9
Xenon Pharmaceuticals Launches $500M Public Offering Following Strong Phase 3 Data
Sentiment: Neutral
View Wiseek Article
XENE
Mar 09, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
9
Xenon's Azetukalner Phase 3 Study Exceeds Expectations with Record Efficacy in Focal Onset Seizures
Sentiment: Positive
View Wiseek Article
XENE
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Xenon's Azetukalner Delivers 'Highest Efficacy Ever' in Phase 3 Epilepsy Study, NDA Submission Planned
Sentiment: Positive
View Wiseek Article